The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E, Howlett J, Porter L, Truman L, Heywood J, Kennet J, Arbon EL, Anselmiova K, Walker NM, Atkar R, Pekalski ML, Rytina E, Evans M, Wicker LS, Todd JA, Mander AP, Bond S, Waldron-Lynch F.
Seelig E, et al. Among authors: howlett j.
JCI Insight. 2018 Oct 4;3(19):e99306. doi: 10.1172/jci.insight.99306.
JCI Insight. 2018.
PMID: 30282826
Free PMC article.
Clinical Trial.